| Literature DB >> 36157536 |
Yong-Chang Zhang1,2, Mou Li2, Yu-Mei Jin2, Jing-Xu Xu3, Chen-Cui Huang3, Bin Song4.
Abstract
BACKGROUND: Tumor deposits (TDs) are not equivalent to lymph node (LN) metastasis (LNM) but have become independent adverse prognostic factors in patients with rectal cancer (RC). Although preoperatively differentiating TDs and LNMs is helpful in designing individualized treatment strategies and achieving improved prognoses, it is a challenging task. AIM: To establish a computed tomography (CT)-based radiomics model for preoperatively differentiating TDs from LNM in patients with RC.Entities:
Keywords: Computed tomography; Differential diagnosis; Lymph node metastasis; Radiomics; Rectal cancer; Tumor deposits
Mesh:
Substances:
Year: 2022 PMID: 36157536 PMCID: PMC9367222 DOI: 10.3748/wjg.v28.i29.3960
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.374
Figure 1Flowchart of patients’ recruitment pathway. RC: Rectal cancer; CT: Computed tomography; TDs: Tumor deposits; LNM: Lymph node metastasis.
Figure 2Radiomics workflow. 3D VOI: Three-dimensional volume of interest; GLCM: Gray level co-occurrence matrix; GLSZM: Gray level size zone matrix; GLRLM: Gray level run length matrix; GLDM: Gray level dependence matrix; NGTDM: Neighbouring gray tone difference matrix; ROC: Receiver operating characteristic curve.
Baseline and clinical characteristics of the included patients
|
|
|
|
|
|
|
|
| Age (mean ± SD, yr) | 59 ± 12 | 61 ± 12 | 0.268 | 60 ± 12 | 60 ± 11 | 0.965 |
| Gender (man/woman) | 49/40 | 63/52 | 0.969 | 94/69 | 18/23 | 0.113 |
| Location (middle-low/high) | 65/24 | 74/41 | 0.187 | 107/56 | 32/9 | 0.128 |
| Neoadjuvant therapy (+/-) | 34/55 | 43/72 | 0.906 | 62/101 | 15/26 | 0.864 |
| CEA (+/-) (positive ≥ 5 ng/mL) | 42/47 | 43/72 | 0.159 | 75/88 | 10/31 | 0.012 |
| CA19-9 (+/-) (positive ≥ 30 U/mL) | 23/66 | 18/97 | 0.072 | 34/129 | 7/34 | 0.589 |
| CA125 (+/-) (positive ≥ 24 U/mL) | 13/76 | 14/101 | 0.611 | 21/142 | 6/35 | 0.767 |
| pT stage (T1/T2/T3/T4) | 0/9/70/10 | 4/12/93/6 | 0.063 | 4/17/127/15 | 0/4/36/1 | 0.894 |
| pN stage (1a/1b/1c/2a/2b) | 0/0/89/0/0 | 52/39/0/15/9 | < 0.001 | 37/33/71/13/9 | 15/6/18/2/0 | 0.115 |
| Histologic EMVI (+/-) | 33/56 | 16/99 | < 0.001 | 41/122 | 8/33 | 0.450 |
| Histologic grade (G1/G2/G3) | 1/63/25 | 0/76/39 | 0.299 | 0/113/50 | 1/26/14 | 0.901 |
| Peritumoral nodule | ||||||
| Shape (irregular/regular) | 12/77 | 2/113 | 0.003 | 11/152 | 3/38 | 0.898 |
| Spiculation (+/-) | 7/82 | 2/113 | 0.077 | 7/156 | 2/39 | 0.871 |
| Size (mm2) (median) | 72.7 | 41.2 | < 0.001 | 54 | 43 | 0.886 |
| CT value (HU) | 61 ± 22 | 65 ± 23 | 0.258 | 64 ± 23 | 63 ± 23 | 0.858 |
| Rad-score 1 (median) | 0.71 | 0.39 | < 0.001 | 0.44 | 0.71 | 0.002 |
| Rad-score 2 (median) | 0.89 | 0.13 | < 0.001 | 0.39 | 0.62 | 0.561 |
Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; CT: Computed tomography; TDs: Tumor deposits; LNM: Lymph node metastasis; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; pT stage: Pathological T stage; pN stage: Pathological N stage; EMVI: Extramural vascular invasion.
Univariate and multivariate logistic regression analysis
|
|
|
| ||
|
|
|
|
|
|
| Age | 0.995 | 0.693 | - | - |
| Gender | 0.820 | 0.534 | - | - |
| Location | 0.819 | 0.282 | - | - |
| CEA | 1.546 | 0.171 | - | - |
| CA19-9 | 1.613 | 0.217 | - | - |
| CA125 | 1.503 | 0.384 | - | - |
| Peritumoral nodule | ||||
| Shape | 14.918 | 0.011 | 0.915 | 0.948 |
| Spiculated (+/-) | 8.400 | 0.051 | - | - |
| Size (mm2) | 1.009 | 0.001 | 0.999 | 0.314 |
| CT value (HU) | 0.994 | 0.364 | - | - |
| Rad-score 1 | 2.946 | < 0.001 | 3.267 | < 0.001 |
| Rad-score 2 | 11.979 | < 0.001 | 14.396 | < 0.001 |
Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA125: Carbohydrate antigen 125; CT: Computed tomography; OR: Odds ratio.
Comparisons of the models in the training, validation, and mixed groups
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rad-score 1 | 0.768 (95%CI: 0.695-0.830) | 66.2% | 70.7% | < 0.001 | 0.700 (95%CI: 0.537-0.833) | 77.8% | 47.8% | 0.032 | - | - | - |
| Combined model | 0.955 (95%CI: 0.910-0.981) | 83.1% | 88.0% | 0.134 | 0.930 (95%CI: 0.805-0.986) | 94.4% | 82.6% | 0.594 | 66.6% | 73.3% | 70.0% |
| Rad-score 2 | 0.940 (95%CI: 0.892-0.971) | 83.1% | 84.8% | 0.918 (95%CI: 0.789-0.981) | 83.3% | 82.6% | 73.3% | 66.6% | 70.0% | ||
The mixed group consisted of 15 double-positive (TDs+LNM+) and 15 single-positive (11 TDs+LNM- and 4 LNM+TDs-) patients. P value: compared with Rad-score 2 by DeLong’s test. Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; TDs: Tumor deposits; LNM: Lymph node metastasis; AUC: Area under the curve; SEN: Sensitivity; SPE: Specificity.
Figure 3Comparisons of the receiver operating characteristic curves, and fit and usefulness evaluation of Rad-score 2. A: In the training set: Area under the curve (AUC) = 0.768 for Rad-score 1, 0.955 for the combined model, and 0.940 for Rad-score 2; B: In the validation set: AUC = 0.700 for Rad-score 1, 0.930 for the combined model, and 0.918 for Rad-score 2; C: The calibration curve of Rad-score 2 shows good agreement between the predicted and observed risks in the training cohort; D: The decision curve demonstrates that Rad-score 2 obtains more benefit than “treat all”, “treat none”, and Rad-score 1. Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; AUC: Area under the curve.
Figure 4Case presentation. A: A 56-year-old man with upper RC, the nodule of TDs (size: 24 mm × 16 mm) had an irregular shape; B: A 44-year-old man with lower RC, the nodule of TDs (size: 14 mm × 11 mm) had a regular oval shape. It is difficult to distinguish TDs and LNM from conventional imaging findings. For these two patients, Rad-score of the largest peritumoral nodule achieved correct diagnosis (values = 0.98 and 0.97, respectively). RC: Rectal cancer; TDs: Tumor deposits; LNM: Lymph node metastasis.
Subgroup analyses of the models in single-positive patients
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
| nCRT | |||||||
| With ( | 0.740 (95%CI: 0.628-0.833) | 73.5% | 74.4% | 0.897 (95%CI: 0.806-0.954) | 73.5% | 90.7% | 0.014 |
| Without ( | 0.753 (95%CI: 0.668-0.825) | 60% | 86.1% | 0.957 (95%CI: 0.905-0.985) | 89.1% | 93.1% | < 0.001 |
| Location | |||||||
| Mid-low ( | 0.782 (95%CI: 0.704-0.848) | 75.4% | 62.2% | 0.931 (95%CI: 0.875-0.967) | 86.2% | 82.4% | < 0.001 |
| High ( | 0.643 (95%CI: 0.515-0.758) | 54.2% | 73.2% | 0.941 (95%CI: 0.853-0.984) | 83.3% | 85.4% | < 0.001 |
| Number of TDs | 1-2 ( | ≥ 3 ( |
| 1-2 ( | ≥ 3 ( |
| |
| Value | 0.64 ± 0.24 | 0.65 ± 0.22 | 0.83 ± 0.22 | 0.77 ± 0.26 | |||
Rad-score 1: Rad-score of the main tumor; Rad-score 2: Rad-score of the largest peritumoral nodule; TDs: Tumor deposits; AUC: Area under the curve; SEN: Sensitivity; SPE: Specificity; nCRT: Neoadjuvant chemoradiotherapy.